Literature DB >> 24966915

Rictor is an independent prognostic factor for endometrial carcinoma.

Shan-Yun Wen1, Chang-Hua Li2, Yan-Li Zhang3, Yu-Hai Bian4, Li Ma5, Qiu-Lin Ge5, Yin-Cheng Teng5, Zhi-Gang Zhang3.   

Abstract

Early-stage endometrial carcinoma (EC) patients have a high cure rate; however, those with high-risk factors may have poor prognosis. Thus, there is an urgent need for searching for new prognostic molecules to more accurately predict survival of patients. We detected the Rictor mRNA expression level in 30 fresh EC tissue and 17 normal endometrial tissue samples with real-time quantitative RT-PCR and Rictor protein expression level in 134 (test cohort) and 115 (validation cohort) paraffin tissue samples by immunohistochemistry, analyzed the correlation between variables and overall survival (OS) using Cox proportional hazards regression, compared the prognostic accuracy of Rictor with other clinicopathological risk factors by logistic regression. The results showed that Rictor mRNA expression of EC is higher than that of normal endometrium; Rictor protein expression level was closely correlated with FIGO stage, grade and vascular invasion in both cohorts; a univariate analysis showed that the pathological type, stage, grade, vascular invasion, lymphatic metastasis and Rictor were predictors of OS in both cohorts; furthermore, multivariate Cox proportional hazards regression analysis indicated that vascular invasion and Rictor were independent prognostic factors for EC in both cohorts; an ROX curve comparison showed that the area under the curve (AUC) for Rictor combined with other clinicopathological prognostic factors was higher than any individual factor or other clinicopathological prognostic factors' combination. Based on the above data, we concluded that Rictor is an independent prognostic factor for EC. It combined with other clinicopathological risk factors was a stronger prognostic model than individual risk factor or their combination.

Entities:  

Keywords:  Rictor; endometrial carcinoma; prognosis

Mesh:

Substances:

Year:  2014        PMID: 24966915      PMCID: PMC4069916     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  38 in total

1.  Role of the integrin-linked kinase (ILK)/Rictor complex in TGFβ-1-induced epithelial-mesenchymal transition (EMT).

Authors:  I Serrano; P C McDonald; F E Lock; S Dedhar
Journal:  Oncogene       Date:  2012-02-06       Impact factor: 9.867

2.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

3.  The human myometrium differentially expresses mTOR signalling components before and during pregnancy: evidence for regulation by progesterone.

Authors:  Helen A Foster; Julie Davies; Ryan C Pink; Serife Turkcigdem; Anastasia Goumenou; David R Carter; Nigel J Saunders; Peter Thomas; Emmanouil Karteris
Journal:  J Steroid Biochem Mol Biol       Date:  2013-03-26       Impact factor: 4.292

Review 4.  Role of Akt/protein kinase B in metabolism.

Authors:  Eileen L Whiteman; Han Cho; Morris J Birnbaum
Journal:  Trends Endocrinol Metab       Date:  2002-12       Impact factor: 12.015

5.  Rictor-dependent AKT activation and inhibition of urothelial carcinoma by rapamycin.

Authors:  Ming-Ju Wu; Chi-Hao Chang; Yung-Tsung Chiu; Mei-Chin Wen; Kuo-Hsiung Shu; Jian-Ri Li; Kun-Yuan Chiu; Yen-Ta Chen
Journal:  Urol Oncol       Date:  2010-03-05       Impact factor: 3.498

6.  Expression of the mTOR pathway regulators in human pituitary adenomas indicates the clinical course.

Authors:  Wang Jia; Andrew J Sanders; Guijun Jia; Xiao Liu; Runchun Lu; Wen G Jiang
Journal:  Anticancer Res       Date:  2013-08       Impact factor: 2.480

7.  Pivotal role of mTOR signaling in hepatocellular carcinoma.

Authors:  Augusto Villanueva; Derek Y Chiang; Pippa Newell; Judit Peix; Swan Thung; Clara Alsinet; Victoria Tovar; Sasan Roayaie; Beatriz Minguez; Manel Sole; Carlo Battiston; Stijn Van Laarhoven; Maria I Fiel; Analisa Di Feo; Yujin Hoshida; Steven Yea; Sara Toffanin; Alex Ramos; John A Martignetti; Vincenzo Mazzaferro; Jordi Bruix; Samuel Waxman; Myron Schwartz; Matthew Meyerson; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2008-08-20       Impact factor: 22.682

Review 8.  mTOR in growth and protection of hypertrophying myocardium.

Authors:  Sundaravadivel Balasubramanian; Rebecca K Johnston; Phillip C Moschella; Santhosh K Mani; William J Tuxworth; Dhandapani Kuppuswamy
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2009-01

9.  Conditional astroglial Rictor overexpression induces malignant glioma in mice.

Authors:  Tariq Bashir; Cheri Cloninger; Nicholas Artinian; Lauren Anderson; Andrew Bernath; Brent Holmes; Angelica Benavides-Serrato; Nesrin Sabha; Robert N Nishimura; Abhijit Guha; Joseph Gera
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

10.  The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells.

Authors:  Akechai Im-aram; Lee Farrand; Seung-Min Bae; Gwonhwa Song; Yong Sang Song; Jae Yong Han; Benjamin K Tsang
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

View more
  7 in total

1.  Superhero Rictor promotes cellular differentiation of mouse embryonic stem cells.

Authors:  Youming Zhu; Peng Wang; Li Zhang; Guo Bai; Chi Yang; Yuanying Wang; Jiacai He; Zhiyuan Zhang; Guoping Zhu; Duohong Zou
Journal:  Cell Death Differ       Date:  2018-08-28       Impact factor: 15.828

2.  Prognostic value of Musashi-1 in endometrioid adenocarcinoma.

Authors:  Li Ma; Yan-Li Xu; Wen-Jing Ding; Hong-Fang Shao; Yin-Cheng Teng
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 3.  The role of metabolic ecosystem in cancer progression - metabolic plasticity and mTOR hyperactivity in tumor tissues.

Authors:  Anna Sebestyén; Titanilla Dankó; Dániel Sztankovics; Dorottya Moldvai; Regina Raffay; Catherine Cervi; Ildikó Krencz; Viktória Zsiros; András Jeney; Gábor Petővári
Journal:  Cancer Metastasis Rev       Date:  2022-01-14       Impact factor: 9.264

4.  Targeting mTORC2 component rictor inhibits cell proliferation and promotes apoptosis in gastric cancer.

Authors:  Yu-Hai Bian; Jia Xu; Wen-Yi Zhao; Zi-Zhen Zhang; Lin Tu; Hui Cao; Zhi-Gang Zhang
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

5.  KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.

Authors:  Emma Cordover; Janet Wei; Chadni Patel; Naing Lin Shan; John Gionco; Davit Sargsyan; Renyi Wu; Li Cai; Ah-Ng Kong; Estela Jacinto; Audrey Minden
Journal:  Chem Res Toxicol       Date:  2020-01-09       Impact factor: 3.973

6.  Maternal folate deficiency causes inhibition of mTOR signaling, down-regulation of placental amino acid transporters and fetal growth restriction in mice.

Authors:  Fredrick J Rosario; Peter W Nathanielsz; Theresa L Powell; Thomas Jansson
Journal:  Sci Rep       Date:  2017-06-21       Impact factor: 4.379

Review 7.  The role of RICTOR downstream of receptor tyrosine kinase in cancers.

Authors:  Ahlem Jebali; Nicolas Dumaz
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.